A pharmaceutical composition comprising: a) a compound A, which is (2R) -2- (4-fluorophenyl) -N- [4- (2 - {[2-methoxy-4- (methylsulfonyl) phenyl] amino} [ 1,2,4] triazolo [1,5- α] pyridin-6-yl) phenyl] propanamide, or a salt, hydrate or solvate thereof； and b1) a matrix B1, said matrix B1 consisting of i. 70% to 100% by weight of polyethylene glycol with an average molecular weight of 100 to 800； ii. 0% to 30% by weight of polyvinylpyrrolidone； and iii. from 0% to 10% by weight of water； and iv. 0% to 5% by weight of one or more pharmaceutically acceptable excipients； wherein the weight ratio of compound A calculated as a solvent free base with respect to matrix B1 is less than 20:80； or b2) a matrix B2, said matrix B2 consisting of i. from 40% to 60% by weight of polyvinylpyrrolidone； ii. 40% to 60% by weight of croscarmellose sodium； and iii. from 0% to 5% by weight of one plus pharmaceutically acceptable excipients； wherein the weight ratio of compound A calculated as a solvent free base with respect to matrix B2 is less than 20:80； or b3) a matrix B3, said matrix B3 consisting of i. from 95% to 100% by weight of a polyethylene glycol with an average molecular weight of 4,000 to 8,000； and ii. 0% to 50% by weight of one or more pharmaceutically acceptable excipients； wherein the weight ratio of compound A calculated as a solvent free base with respect to matrix B3 is less than 30:70.Una composición farmacéutica que comprende: a) un compuesto A, que es (2R)-2-(4-fluorofenil)-N-[4-(2-{[2-metoxi-4-(metilsulfonil)fenil]amino}[1,2,4]triazolo[1,5- α]piridin-6-il)fenil]propanamida, o una sal, hidrato o solvato del mismo； y b1) una matriz B1, dicha matriz B1 que consiste en i. del 70 % al 100 % en peso de polietilenglicol con un peso molecular promedio de 100 a 800； ii. del 0 % al 30 % en peso de polivinilpirrolidona； y iii. del 0 % al 10 % en peso de agua； y iv. del 0 % al 5 % en peso de uno o más excipientes farmacéuticamente aceptables； en la que la relación en peso d
